← Leaderboards
John Zapata Metcalfe
University Of California, San Francisco
$8,956,853
Attributed
$16,237,407
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2011–25$2.5M$1.9M$1.3M$625K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,237,407 · 7
By mechanism
R01$12,562,664 · 4
D43$2,599,214 · 1
K23$625,050 · 1
R21$450,479 · 1
Top collaborators
- David M Engelthaler10 shared
- Monica Gandhi5 shared
- Arthur L. Reingold4 shared
- Soumitesh Chakravorty3 shared
- James Gita Hakim3 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- David M Engelthaler$4,210,794
- Payam Nahid$19,473,523
- Radojka Savic$8,230,011
- Charles Yen Chiu$12,010,203
- Charles Langelier$4,048,645
Others in their field
Top investigators on “United States National Institutes Of Health”
- Leonard Freedman · Leidos Biomedical Research, Inc.$816,847,401
- Sonia M Thomas · Research Triangle Institute$701,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$642,073,624
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$513,687,120
- Tracy L Nolen · Research Triangle Institute$474,487,152
Research focus
United States National Institutes Of HealthPharmaceutical PreparationsSpecimenTuberculosis TreatmentFundingDrug Resistance In TuberculosisResourcesTreatment ProtocolsRegimenResistancePredispositionMolecularTuberculosis DrugsTreatment OutcomeMedicineTransmission ProcessMultidrug-Resistant TuberculosisAids Clinical Trial GroupPyrazinamideSputumDetectionDrug ResistanceClinical TrialsHiv/Tb
Grant awards (34)
A novel cartridge-based sequencing solution for decentralized M. tuberculosis resistance detection$700,104
R01 · FY2025 · AI · contact PI
Handheld and population-based sequencing for rapid detection of new and repurposed drug resistance in M. tuberculosis$413,869
R01 · FY2025 · AI · contact PI
Handheld and population-based sequencing for rapid detection of new and repurposed drug resistance in M. tuberculosis$290,717
R01 · FY2025 · AI · contact PI
Comprehensive characterization of Rv0678 bedaquiline resistance-conferring polymorphisms$246,000
R21 · FY2025 · AI · contact PI
Handheld and population-based sequencing for rapid detection of new and repurposed drug resistance in M. tuberculosis$708,266
R01 · FY2024 · AI · contact PI
A novel cartridge-based sequencing solution for decentralized M. tuberculosis resistance detection$703,128
R01 · FY2024 · AI · contact PI
Comprehensive characterization of Rv0678 bedaquiline resistance-conferring polymorphisms$204,479
R21 · FY2024 · AI · contact PI
Handheld and population-based sequencing for rapid detection of new and repurposed drug resistance in M. tuberculosis$745,941
R01 · FY2023 · AI · contact PI
Novel next-generation sequencing assay for monitoring multidrug resistant tuberculosis treatment in the setting of HIV infection$736,217
R01 · FY2023 · AI · contact PI
A novel cartridge-based sequencing solution for decentralized M. tuberculosis resistance detection$730,369
R01 · FY2023 · AI · contact PI
Training for Research Excellence and MeNtorship in Tuberculosis (TRENT)$300,385
D43 · FY2022 · TW · contact PI
Handheld and population-based sequencing for rapid detection of new and repurposed drug resistance in M. tuberculosis$793,285
R01 · FY2021 · AI · contact PI
Novel next-generation sequencing assay for monitoring multidrug resistant tuberculosis treatment in the setting of HIV infection$732,119
R01 · FY2021 · AI · contact PI
Training for Research Excellence and MeNtorship in Tuberculosis (TRENT)$300,384
D43 · FY2021 · TW · contact PI
Novel next-generation sequencing assay for monitoring multidrug resistant tuberculosis treatment in the setting of HIV infection$731,288
R01 · FY2020 · AI · contact PI
Novel methods of pharmacologic monitoring for multidrug resistant tuberculosis treatment in the setting of HIV infection$670,213
R01 · FY2020 · AI · contact PI
Training for Research Excellence and MeNtorship in Tuberculosis (TRENT)$300,550
D43 · FY2020 · TW · contact PI
Novel next-generation sequencing assay for monitoring multidrug resistant tuberculosis treatment in the setting of HIV infection$912,893
R01 · FY2019 · AI · contact PI
Novel methods of pharmacologic monitoring for multidrug resistant tuberculosis treatment in the setting of HIV infection$690,151
R01 · FY2019 · AI · contact PI
Training for Research Excellence and MeNtorship in Tuberculosis (TRENT)$301,299
D43 · FY2019 · TW · contact PI
Novel next-generation sequencing assay for monitoring multidrug resistant tuberculosis treatment in the setting of HIV infection$790,569
R01 · FY2018 · AI · contact PI
Novel methods of pharmacologic monitoring for multidrug resistant tuberculosis treatment in the setting of HIV infection$696,561
R01 · FY2018 · AI · contact PI
Training for Research Excellence and MeNtorship in Tuberculosis (TRENT)$305,300
D43 · FY2018 · TW · contact PI
Novel methods of pharmacologic monitoring for multidrug resistant tuberculosis treatment in the setting of HIV infection$751,593
R01 · FY2017 · AI · contact PI
HIV Implementation Science Research Training Program$272,824
D43 · FY2017 · TW
Novel methods of pharmacologic monitoring for multidrug resistant tuberculosis treatment in the setting of HIV infection$765,381
R01 · FY2016 · AI · contact PI
HIV Implementation Science Research Training Program$272,824
D43 · FY2016 · TW
HIV Implementation Science Research Training Program$272,824
D43 · FY2015 · TW
Improving Early Identification of Drug Resistant Tuberculosis in HIV Prevalent Se$125,010
K23 · FY2015 · AI · contact PI
HIV Implementation Science Research Training Program$272,824
D43 · FY2014 · TW
Improving Early Identification of Drug Resistant Tuberculosis in HIV Prevalent Se$125,010
K23 · FY2014 · AI · contact PI
Improving Early Identification of Drug Resistant Tuberculosis in HIV Prevalent Se$125,010
K23 · FY2013 · AI · contact PI
Improving Early Identification of Drug Resistant Tuberculosis in HIV Prevalent Se$125,010
K23 · FY2012 · AI · contact PI
Improving Early Identification of Drug Resistant Tuberculosis in HIV Prevalent Se$125,010
K23 · FY2011 · AI · contact PI